Justin Chakma serves as Executive at ARS Pharmaceuticals, Inc., where they oversee executive responsibilities. Since joining the company, Justin Chakma has executed 4 insider transactions totaling $1.5M, demonstrating a bearish approach to their equity position. Their most recent transaction on Nov 12, 2025 involved exercising options for 30,000 shares valued at $25.2K.
Justin Chakma currently holds 166,380 shares of ARS Pharmaceuticals, Inc. (SPRY), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Justin Chakma has been a net seller of SPRY stock. They have purchased $0 and sold $1.5M worth of shares.
Justin Chakma's most recent insider trade was on Nov 12, 2025, when they sold 30,000 shares at $0.84 per share.
Get notified when new Form 4 filings are submitted
| $8.91 |
| Discretionary |
| Nov 12, 2025 | SPRY | $1.2M | Sale | 136,380 | $8.86 | Discretionary |
| Nov 8, 2022 | SPRY | $0 | Award | 236,380 | $N/A | Discretionary |